Autogene cevumeran goes on hold in adjuvant bladder cancer.
ApexOnco Front Page
Recent articles
9 July 2025
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
2 December 2024
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
29 November 2024
Party season approaches; but first, conferences.
27 November 2024
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
26 November 2024
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
25 November 2024
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
22 November 2024
But could toxicity be holding back filing plans?